Dermatological Market (By Dermatological Disease: Acne, Dermatitis, Psoriasis, Skin Cancer, Rosacea, Alopecia; By Drug Type: Prescription-Based Drugs, Over-the-Counter Drugs; By Route of Administration: Topical, Oral, Parenteral Administration) – Global Industry Analysis, Market Size, Opportunities and Forecast, 2020 - 2027

The global dermatologicals market is anticipated to grow at a CAGR of around 10.7% during the forecast period 2020 to 2027 and to reach around US$ 38.2 Bn by 2027.

Market Dynamics

Gradual increase in number of patients suffering from skin-associated diseases, rising awareness among consumers related to dermatological, and increasing demand for treatment related to skin cancer, rosacea, alopecia, etc. are major factors expected to drive the growth of global market.

According to American Cancer Society, Inc. about 5.4 million basal and squamous cell skin cancers are diagnosed each year in the US and about 8 out of 10 of these are basal cell cancers.

Government is spending high for the development of present infrastructure for R&D activities, coupled with developing regulatory scenarios are among other factors expected to support the growth of target market.

Major players are focused on business development activities through strategic merger and acquisitions which are factors expected to increase the customer base and enhance the profit ratio this is expected to further augment the growth of target market.

• In 2020, Eli Lilly acquired Dermira a dermatological drugs developer for US$ 1.01 Bn this acquisition is expected to help the company to expand the product portfolio and increase the profit ratio.

In addition, government in collaboration with private players is focused on introducing new products which is expected to further support the growth of target market to a certain extent.

• In 2019, L'Oréal introduced AF Adapalene Gel an over-the-counter product treatment for acne-prone skin. This is expected to increase the customer base and enhance the product portfolio.
• In 2017, Merck and Pfizer in collaboration launched Bavencio in the UK market the first medicine to be licensed for the treatment of the rare, aggressive skin cancer of metastatic Merkel Cell Carcinoma (mMCC).

However, factors such as stringent government regulations related to product approval and side effects of some drugs are expected to hamper the growth of the global market. In addition, lack of awareness in developing countries and limited availability of reimbursement policies are among other factors expected to challenge the growth of target market.

Advancements in drug development by major players and inclination towards emerging economies in order to increase the customer base and enhance the profit ratio are factor expected to create new opportunities for players over the forecast period. In addition, high R&D activities and new product offerings are factors expected to revenue support the target market growth.

Dermatological Market Segment Analysis, 2019

The global dermatological market is segmented in to dermatological disease, drug type, and route of administration. The dermatological disease is further bifurcated in to acne, dermatitis, psoriasis, skin cancer, rosacea, and alopecia. Among drug type the over-the-counter drugs is expected to witness faster growth in the coming years.

Segment Analysis by Region

The market in North America is expected to account for significant revenue share owing to availability of advanced infrastructure for R&D activities and facilitate the adoption of devices. In addition, favorable government policies and presence of major players operating in the country along with new product introduction is another factor expected to further support the growth of regional market.

Asia Pacific is expected to witness faster growth in the near future owing to increase in number of patients suffering from skin disorder. In addition, developing regulatory scenario and innovative product offerings by regional players is expected to further support the growth of target market.

Competitive Landscape

The global market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.

Report coverage

The market research study on “Dermatological Market (Dermatological Disease: Acne, Dermatitis, Psoriasis, Skin Cancer, Rosacea, and Alopecia; Drug Type: Prescription-Based Drugs and Over-the-Counter Drugs; Route of Administration: Topical, Oral, and Parenteral Administration) – Global Industry Analysis, Market Size, Opportunities and Forecast, 2020 - 2027”, offers a detailed insights on the global dermatological market entailing insights on its different market segments. Market dynamics with drivers, restraints and opportunities with their impact are provided in the report. The report provides insights on global dermatologicals market segment by dermatological disease, drug type, route of administration and major geographic regions. The report covers basic development policies and layouts of technology development processes. Secondly, the report covers global dermatologicals market size and segment markets by dermatological disease, drug type, route of administration and geography along with the information on companies operating in the market. The dermatological market analysis is provided for major regional market including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. For each region, the market size for different segments has been covered under the scope of report. The players profiled in the report Merck KGaA, Bayer AG, Johnson & Johnson, Novartis AG, GlaxoSmithKline plc, AstraZeneca, Galderma S.A., Amgen Inc., AbbVie Inc., and Pfizer Inc.

Market Segmentation

Market By Dermatological Disease

• Acne
• Dermatitis
• Psoriasis
• Skin Cancer
• Rosacea
• Alopecia
  
  

Market By Drug Type

• Prescription-Based Drugs
• Over-the-Counter Drugs
  
  

Market By Route of Administration

• Topical
• Oral
• Parenteral Administration

Market By Region

North America

• U.S.
• Canada

Europe

• UK.
• Germany
• France
• Spain
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC
• South Africa
• Rest of Middle East & Africa